カテゴリ： GlobalData, イスラエル, 企業調査

Teva Pharmaceutical Industries Ltd (TEVA)：医療機器：M&Aディール及び事業提携情報

◆英語タイトル：Teva Pharmaceutical Industries Ltd (TEVA) - Medical Equipment - Deals and Alliances Profile
◆商品コード：DATA904C7194
◆発行会社（調査会社）：GlobalData
◆発行日：2018年10月
◆ページ数：145
◆レポート言語：英語
◆レポート形式：PDF
◆納品方法：Eメール
◆対象地域：イスラエル
◆産業分野：医療機器
◆販売価格オプション（消費税別）
Single User（1名様閲覧用）USD250 ⇒換算￥37,000見積依頼/購入/質問フォーム
Site License（同一事業所内共有可）USD500 ⇒換算￥74,000見積依頼/購入/質問フォーム
Enterprisewide License（複数事業所内共有可）USD750 ⇒換算￥111,000見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※本体価格が￥30,000未満のレポートにつきましては、ハンドリングチャージ￥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
※GlobalData社の概要はこちらでご確認いただけます。

このエントリーをはてなブックマークに追加
LINEで送る


【レポートの概要】

Summary
Teva Pharmaceutical Industries Ltd (Teva) is a pharmaceutical company that carries out the research, development, manufacture and commercialization of generic and specialty medicines. It provides specialty medicines to treat disorders of the central nervous system (CNS), respiratory, cancer, women’s health and other therapy areas. The company offers generic medicines in a range of dosage forms including capsules, tablets, injectables, liquids, inhalants, creams and ointments. Teva also provides over-the-counter (OTC) products, besides active pharmaceutical ingredients (APIs). It carries out OTC business principally through PGT Healthcare, a consumer healthcare joint venture with The Procter & Gamble Company (P&G). The company conducts its worldwide operations through a network of global subsidiaries. Teva is headquartered in Petach Tikva, Israel.

Teva Pharmaceutical Industries Ltd (TEVA) – Medical Equipment – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Medical eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 6
Teva Pharmaceutical Industries Ltd, Medical Equipment, Deals By Year, 2012 to YTD 2018 7
Teva Pharmaceutical Industries Ltd, Medical Equipment Deals By Type, 2012 to YTD 2018 8
Teva Pharmaceutical Industries Ltd, Medical Equipment, Deals By Region, 2012 to YTD 2018 9
Teva Pharmaceutical Industries Ltd, Medical Equipment, Deals By Market, 2012 to YTD 2018 10
Teva Pharmaceutical Industries Ltd, Medical Equipment, Deals Summary, 2012 to YTD 2018 11
Teva Pharmaceutical Industries Ltd, Medical Equipment, Deal Details 14
Venture Financing 14
Gamida Cell Raises US$10 Million In Series E Financing 14
Teva Pharma Industries Invests In MultiGene Vascular Systems 16
Partnerships 17
Teva Pharma Enters into Licensing Agreement with ProBioGen 17
Teva Pharma Enters into Licensing Agreement with Paxman Coolers 18
Teva Pharma Enters into Licensing Agreement with Brain Resource 19
Celmatix Enters into Partnership with Oncotest-Teva 20
Teva Pharma Enters into Agreement with Syqe Medical 21
Teva Pharma Enters into Agreement with Intel 22
MDxHealth Enters into Distribution Agreement with Teva Pharmaceutical 23
Oncotest-Teva Enters into Distribution Agreement with Guardant Health 24
Teva Pharma Enters into an Agreement with Microchips Biotech 25
MDxHealth Enters Into Agreement With Teva Pharma To Commercialize Two Cancer Tests In Israel 26
Teva Pharma Enters Into Co-Marketing Agreement With Verinata Health For Verifi Test 27
Equity Offering 28
Biotime Plans to Raise up to USD15 Million in Public Offering of Shares 28
Teva Pharma Announces Underwriters Exercise of Over-Allotment of American Depositary Shares 30
Teva Pharma Announces Underwriters Exercise of Over-Allotment of Preferred Shares 32
American Well Raises USD10 Million in Private Placement of Shares 34
Debt Offering 35
Teva Pharma Prices Private Placement of 3.25% Notes Due 2022 for USD866.3 Million 35
Teva Pharma Prices Private Placement of 4.5% Notes Due 2025 for USD1,113.8 Million 36
Teva Pharma Prices Private Placement of 6.75% Notes Due 2028 for USD1.25 Billion 37
Teva Pharma Prices Private Placement of 6% Notes Due 2024 for USD1.25 Billion 38
Teva Pharma Plans to Raise USD5,000 Million in Public Offering of Debt Securities 39
Teva Pharma Raises USD304 Million in Public Offering of 0.125% Notes Due 2018 40
Teva Pharma Raises USD354.6 Million in Public Offering of 1% Notes Due 2025 42
Teva Pharma Raises USD354.6 Million in Public Offering of 0.5% Notes Due 2022 44
Teva Pharma Raises USD1.65 Billion in Additional Public Offering of 1.125% Notes Due 2024 46
Teva Pharma Raises USD1.93 Billion in Additional Public Offering of 0.375% Notes Due 2020 48
Teva Pharma Raises USD820 Million in Additional Public Offering of 1.625% Notes Due 2028 50
Teva Pharma Raises USD3 Billion in Public Offering of 2.8% Notes Due 2023 52
Teva Pharma Raises USD1.5 Billion in Public Offering of 1.4% Notes Due 2018 54
Teva Pharma Raises USD2 Billion in Public Offering of 1.7% Notes Due 2019 56
Teva Pharma Raises USD2 Billion in Public Offering of 4.1% Notes Due 2046 58
Teva Pharma Raises USD3.5 Billion in Public Offering of 3.15% Notes Due 2026 60
Teva Pharma Raises USD3 Billion in Public Offering of 2.2% Notes Due 2021 62
Teva Pharma Plans to Raise USD22 Billion in Public Offering of Bonds 64
Asset Transactions 65
CooperSurgical Acquires PARAGARD from Teva Pharma for USD1.1 Billion 65
Acquisition 67
Allergan to Sell 10% Stake in Teva Pharma 67
Teva Pharma Sells Stake in Mesoblast 68
Teva Pharma Acquires Gecko Health Innovations 69
Teva Pharma Completes Acquisition Of NuPathe 70
Omron Healthcare To Acquire Minority Stake In Atonomics, Care Diagnostics Company 72
Teva Pharma Completes Acquisition of MicroDose Therapeutx 74
Celltrion Chairman Jung Jin Seo Plans To Sell Controlling Stake In The Company 75
Teva Pharmaceutical Industries Ltd – Key Competitors 77
Teva Pharmaceutical Industries Ltd – Key Employees 78
Teva Pharmaceutical Industries Ltd – Locations And Subsidiaries 80
Head Office 80
Other Locations & Subsidiaries 80
Joint Venture 89
Recent Developments 90
Financial Announcements 90
Aug 02, 2018: Teva reports second quarter 2018 financial results 90
May 03, 2018: Teva Reports First Quarter 2018 Financial Results 95
Feb 08, 2018: Teva Reports 2017 Full Year and Fourth Quarter Financial Results 100
Nov 02, 2017: Teva Reports Third Quarter 2017 Financial Results 108
Aug 03, 2017: Teva Reports Second Quarter 2017 Financial Results 112
May 11, 2017: Teva Reports First Quarter 2017 Financial Results 114
Feb 13, 2017: Teva Reports Full Year and Fourth Quarter 2016 Financial Results 118
Jan 06, 2017: Teva Provides 2017 Financial Outlook 126
Corporate Communications 128
Oct 30, 2017: Kare Schultz to Join Teva as President and Chief Executive Officer 128
Sep 19, 2017: Teva Completes Amendment to Credit Facilities 129
Sep 11, 2017: Teva Names Kare Schultz as President and Chief Executive Officer 130
Jul 23, 2017: Teva to Terminate Around 300 jobs in Israel 132
Jul 13, 2017: Teva Enhances Board of Directors as All Proposals Approved at Annual General Meeting of Shareholders 133
Apr 26, 2017: Teva Announces Planned Departure of Eyal Desheh, Group Executive Vice President and Chief Financial Officer 134
Feb 06, 2017: Teva Appoints Dr. Yitzhak Peterburg as Interim Chief Executive Officer, Succeeding Erez Vigodman 135
Product News 137
Feb 05, 2018: Amiko receives CE mark for three novel inhaler sensors 137
Other Significant Developments 138
Jul 17, 2018: Teva Highlights Key Milestones Achieved in the 2017 Social Impact Report 138
Dec 14, 2017: Teva Announces Restructuring Plan and Additional Measures to Improve Its Business and Financial Performance 139
Nov 27, 2017: Teva Announces New Organization Structure and Leadership Changes 141
Nov 21, 2017: Accelerating the Evolution of Pharma’s Digital Landscape – Practices from Viseven 144
Appendix 145
Methodology 145
About GlobalData 145
Contact Us 145
Disclaimer 145

List of Tables
Teva Pharmaceutical Industries Ltd, Medical Equipment, Key Facts, 2017 2
Teva Pharmaceutical Industries Ltd, Medical Equipment, Deals Summary, 2012 to YTD 2018 2
Teva Pharmaceutical Industries Ltd, Medical Equipment, Deals By Year, 2012 to YTD 2018 7
Teva Pharmaceutical Industries Ltd, Medical Equipment Deals By Type, 2012 to YTD 2018 8
Teva Pharmaceutical Industries Ltd, Medical Equipment, Deals By Region, 2012 to YTD 2018 9
Teva Pharmaceutical Industries Ltd, Deals By Market, 2012 to YTD 2018 10
Teva Pharmaceutical Industries Ltd, Medical Equipment, Deals Summary, 2012 to YTD 2018 11
Gamida Cell Raises US$10 Million In Series E Financing 14
Teva Pharma Industries Invests In MultiGene Vascular Systems 16
Teva Pharma Enters into Licensing Agreement with ProBioGen 17
Teva Pharma Enters into Licensing Agreement with Paxman Coolers 18
Teva Pharma Enters into Licensing Agreement with Brain Resource 19
Celmatix Enters into Partnership with Oncotest-Teva 20
Teva Pharma Enters into Agreement with Syqe Medical 21
Teva Pharma Enters into Agreement with Intel 22
MDxHealth Enters into Distribution Agreement with Teva Pharmaceutical 23
Oncotest-Teva Enters into Distribution Agreement with Guardant Health 24
Teva Pharma Enters into an Agreement with Microchips Biotech 25
MDxHealth Enters Into Agreement With Teva Pharma To Commercialize Two Cancer Tests In Israel 26
Teva Pharma Enters Into Co-Marketing Agreement With Verinata Health For Verifi Test 27
Biotime Plans to Raise up to USD15 Million in Public Offering of Shares 28
Teva Pharma Announces Underwriters Exercise of Over-Allotment of American Depositary Shares 30
Teva Pharma Announces Underwriters Exercise of Over-Allotment of Preferred Shares 32
American Well Raises USD10 Million in Private Placement of Shares 34
Teva Pharma Prices Private Placement of 3.25% Notes Due 2022 for USD866.3 Million 35
Teva Pharma Prices Private Placement of 4.5% Notes Due 2025 for USD1,113.8 Million 36
Teva Pharma Prices Private Placement of 6.75% Notes Due 2028 for USD1.25 Billion 37
Teva Pharma Prices Private Placement of 6% Notes Due 2024 for USD1.25 Billion 38
Teva Pharma Plans to Raise USD5,000 Million in Public Offering of Debt Securities 39
Teva Pharma Raises USD304 Million in Public Offering of 0.125% Notes Due 2018 40
Teva Pharma Raises USD354.6 Million in Public Offering of 1% Notes Due 2025 42
Teva Pharma Raises USD354.6 Million in Public Offering of 0.5% Notes Due 2022 44
Teva Pharma Raises USD1.65 Billion in Additional Public Offering of 1.125% Notes Due 2024 46
Teva Pharma Raises USD1.93 Billion in Additional Public Offering of 0.375% Notes Due 2020 48
Teva Pharma Raises USD820 Million in Additional Public Offering of 1.625% Notes Due 2028 50
Teva Pharma Raises USD3 Billion in Public Offering of 2.8% Notes Due 2023 52
Teva Pharma Raises USD1.5 Billion in Public Offering of 1.4% Notes Due 2018 54
Teva Pharma Raises USD2 Billion in Public Offering of 1.7% Notes Due 2019 56
Teva Pharma Raises USD2 Billion in Public Offering of 4.1% Notes Due 2046 58
Teva Pharma Raises USD3.5 Billion in Public Offering of 3.15% Notes Due 2026 60
Teva Pharma Raises USD3 Billion in Public Offering of 2.2% Notes Due 2021 62
Teva Pharma Plans to Raise USD22 Billion in Public Offering of Bonds 64
CooperSurgical Acquires PARAGARD from Teva Pharma for USD1.1 Billion 65
Allergan to Sell 10% Stake in Teva Pharma 67
Teva Pharma Sells Stake in Mesoblast 68
Teva Pharma Acquires Gecko Health Innovations 69
Teva Pharma Completes Acquisition Of NuPathe 70
Omron Healthcare To Acquire Minority Stake In Atonomics, Care Diagnostics Company 72
Teva Pharma Completes Acquisition of MicroDose Therapeutx 74
Celltrion Chairman Jung Jin Seo Plans To Sell Controlling Stake In The Company 75
Teva Pharmaceutical Industries Ltd, Key Competitors 77
Teva Pharmaceutical Industries Ltd, Key Employees 78
Teva Pharmaceutical Industries Ltd, Subsidiaries 80
Teva Pharmaceutical Industries Ltd, Joint Venture 89

List of Figures
Teva Pharmaceutical Industries Ltd, Medical Equipment, Deals by Type, 2012 to YTD 2018 2
Teva Pharmaceutical Industries Ltd, Medical Equipment, Deals By Year, 2012 to YTD 2018 2
Teva Pharmaceutical Industries Ltd, Medical Equipment, Deals By Region, 2012 to YTD 2018 2
Teva Pharmaceutical Industries Ltd, Medical Equipment, Deals By Market, 2012 to YTD 2018 2
Teva Pharmaceutical Industries Ltd, Medical Equipment, Deals By Year, 2012 to YTD 2018 7
Teva Pharmaceutical Industries Ltd, Medical Equipment, Deals by Type, 2012 to YTD 2018 8
Teva Pharmaceutical Industries Ltd, Medical Equipment, Deals By Region, 2012 to YTD 2018 9
Teva Pharmaceutical Industries Ltd, Medical Equipment, Deals by Market, 2012 to YTD 2018 10

★海外企業調査レポート[Teva Pharmaceutical Industries Ltd (TEVA)：医療機器：M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら
■おすすめ企業レポート■
  • Sumitomo Metal Mining Co Ltd：戦略・SWOT・企業財務分析
    Sumitomo Metal Mining Co Ltd - Strategy, SWOT and Corporate Finance Report Summary Sumitomo Metal Mining Co Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and s …
  • Kaiser Foundation Health Plan Inc：企業の戦略的SWOT分析
    Kaiser Foundation Health Plan Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major p …
  • Ascena Retail Group Inc (ASNA)：企業の財務・戦略的SWOT分析
    Ascena Retail Group Inc (ASNA) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakn …
  • Dai Nippon Printing Co Ltd (7912)：企業の財務・戦略的SWOT分析
    Dai Nippon Printing Co Ltd (7912) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and we …
  • DaVita Inc (DVA)-医療機器分野：企業M&A・提携分析
    Summary DaVita Inc (DaVita), formerly DaVita HealthCare Partners Inc., is a provider of dialysis services and integrated health care delivery and management services. The company is a provider of dialysis services in the US for patients with chronic kidney failure and end-stage renal disease (ESRD). …
  • AIT Austrian Institute of Technology GmbH：医療機器：M&Aディール及び事業提携情報
    Summary AIT Austrian Institute of Technology GmbH (AIT) is a research and technology organisation which provides research and development services. The institute provides research and technological development for infrastructure related technologies in the fields of energy, mobility systems, low-emi …
  • Groupe SEB S.A. (SK)：企業の財務・戦略的SWOT分析
    Groupe SEB S.A. (SK) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • Mitsubishi Logistics Corporation：企業の戦略・SWOT・財務分析
    Mitsubishi Logistics Corporation - Strategy, SWOT and Corporate Finance Report Summary Mitsubishi Logistics Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, produ …
  • Gene Techno Science Co Ltd (4584)：製薬・医療：M&Aディール及び事業提携情報
    Summary Gene Techno Science Co Ltd (GTS) is a developer and marketer of drug and antibodies for intractable diseases, cancer, and rare diseases. The company develops biological and biosimilar products. Its biological pipeline products include GND-004, for oncology; GND-001 for immunological disease …
  • Magellan Midstream Partners LP (MMP)：企業の財務・戦略的SWOT分析
    Magellan Midstream Partners LP (MMP) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and …
  • Jacobs Engineering Group Inc (JEC)：電力：M&Aディール及び事業提携情報
    Summary Jacobs Engineering Group Inc (Jacobs) is a professional services company. It offers a diverse range of technical, professional, and construction services. The company's service portfolio includes project; process, scientific and specialty consulting; engineering and construction; and operati …
  • Alzheimer’s Drug Discovery Foundation：製薬・医療：M&Aディール及び事業提携情報
    Summary Alzheimer's Drug Discovery Foundation (ADDF), formerly Institute for the Study of Aging is a drug discovery foundation. The foundation offers funds for drug discovery and development research programs in the field of Alzheimer’s disease, related dementias and cognitive aging. It offers servi …
  • Alexza Pharmaceuticals Inc：企業の戦略的SWOT分析
    Alexza Pharmaceuticals Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products …
  • Tompkins Financial Corp (TMP)：企業の財務・戦略的SWOT分析
    Tompkins Financial Corp (TMP) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakne …
  • Novo Nordisk AS (NOVO B)-医療機器分野：企業M&A・提携分析
    Summary Novo Nordisk A/S (Novo Nordisk), a subsidiary of Novo A/S discovers, develops and manufactures innovative biological medicines. It focuses at developing drugs for treating diabetes and other serious chronic conditions including hemophilia, growth disorders and obesity. The company’s product …
  • Charles River Laboratories International, Inc.：企業の戦略・SWOT・財務情報
    Charles River Laboratories International, Inc. - Strategy, SWOT and Corporate Finance Report Summary Charles River Laboratories International, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, ope …
  • Ostfold Energi AS：企業の戦略的SWOT分析
    Ostfold Energi AS - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and serv …
  • Baron Oil Plc (BOIL)：企業の財務・戦略的SWOT分析
    Summary Baron Oil Plc (Baron Oil), formerly Gold Oil PLC is an oil and gas exploration and production company. The company identifies and develops crude oil and natural gas interests in Latin America including Peru and Colombia. It also holds working interests of Nancy Burdine Maxine oil field, oil …
  • LifeWatch AG (LIFE)-医療機器分野：企業M&A・提携分析
    Summary LifeWatch AG (LifeWatch) is a healthcare technology and solutions company. It provides monitoring services and develops, manufactures, and markets advanced telehealth systems for high-risk and chronically ill patients. The company’s major services include mobile cardiac telemetry service, st …
  • Pearson plc：企業の戦略・SWOT・財務情報
    Pearson plc - Strategy, SWOT and Corporate Finance Report Summary Pearson plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate act …

◆H&Iグローバルリサーチ株式会社のお客様（例）◆